D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC.

Abstract excerpt

In non-small cell lung cancer (NSCLC), the overexpression or abnormal activation of epidermal growth factor receptor (EGFR) is associated with tumor progression and drug resistance. EGFR tyrosine kinase inhibitors (TKIs) are currently the first-line treatment of NSCLC. However, patients inevitably acquired EGFR TKIs resistance mutations, which led to disease progression, so it is urgent to find new treatment....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
• Share to Carcinoma, Non-Small-Cell Lung